Is second course intravesical bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful?

Acta Urologica Japonica

Volumn 51, Issue 8, 2005, Pages 539-543

  Yamada, Yuji ^a   Hara, Isao ^a   Kumano, Masafumi ^a   Furukawa, Junnya ^a   Yamanaka, Kazuki ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

BCG; Bladder; Carcinoma in situ; Second course

Indexed keywords

BCG VACCINE;

ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER THERAPY; CARCINOMA IN SITU; CLINICAL ARTICLE; CYSTECTOMY; FOLLOW UP; HUMAN; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA IN SITU; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 24644441343     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Morales A, Eidinger D and Bruce AW: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116: 180-183, 1976
2. Kim JC and Steinberg GD: The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. J Urol 165: 745-756, 2001
3. Harland SJ, Charig CR, Highman W, et al.: Outcome in carcinoma in situ of bladder treated with intravesical bacilli Calmette-Guerin. Br J Urol 70: 271-275, 1992
4. Sylvester RJ, van der Meijden and Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168: 1964-1970, 2002
5. Jakse G, Hall R, Bono A, et al.: Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU group phase II protocol 30861. Eur Urol 40: 144-150, 2001
6. De Jager R, Guinan P, Lamm DL, et al.: Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette-Guerin. overview analysis of six phase II clinical trials. Urology 38: 507-513, 1991
7. Nadler RB, Catalona WJ, Hudson MA, et al.: Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol 152: 367-373, 1994
8. Coplen DE, Marcus MD, Myers JA, et al. : Long-term followup of patients treated with 1 or 2, 6 week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol 144: 652-657, 1990
9. Griffith TRL, Charton M, Neal DE, et al.: Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 167: 2408-2412, 2002
10. Herr HW and Dalbagni G: Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 169: 1706-1708, 2003
11. Catalona WJ, Hudson MA, Gillen DP, et al.: Risk and benefits of repeated courses of intravesical bacillus Camette-Guerin therapy for superficial bladder cancer. J Urol 137: 220-224, 1987
12. Lamm DL, Blumenstein BA, Crissman JD, et al.: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 163: 1124-1129, 2000
13. Palou J, Laguna P, Millan-Rodriguez F, et al.: Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol 165: 1488-1491, 2001
14. Bui TT and Schellhammer PF: Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 49: 687-691, 1997
15. Bretton PR, Herr HW, Kimmel M, et al.: The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin. J Urol 143: 710-713, 1990
16. O'Donnell MA, Lilli K, Leopold C, et al.: Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172: 888-893, 2004
17. Phase I trial of intravesical Gemcitabine in bacillus Calmette-Guerin-refractory transitional carcinoma of the bladder. J Clin Oncol 20: 3193-3198, 2002
18. Herr WH and Sogani PC: Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166: 1296-1299, 2001